8 November 2017
The Cabinet Office has announced the appointment of Dr Patrick Vallance as the new government Chief Scientific Adviser. Dr Vallance, who is currently President of Research and Development, at GlaxoSmithKline, and the former Head of Medicine at University College London, will take up the post in Spring 2018. In response, the British Society for Immunology has issued the following statement.
Professor Peter Openshaw, President of the British Society for Immunology, said:
“The news that Patrick Vallance has accepted the role of the UK’s Chief Scientific Adviser will be welcomed by all those working in the life sciences. Dr Vallance’s experience of academic and commercial research at the highest level provides a great foundation for our developing research base in the coming years, especially as the UK looks to develop and implement its new Life Sciences Industrial Strategy. Drug and vaccine development are key areas in which UK science currently excels, and his support to these areas will be important.
“The use of accurate scientific evidence in policy decisions is vital and Dr Vallance will provide a bridge between the scientific community and Government. We look forward to welcoming Dr Vallance to the role and working with him to ensure not only that scientific evidence continues to be an integral part of policy decisions, but also that Government and ministers are effective in supporting and enabling the life sciences sector to grow in line with the Industrial Strategy.”
The full announcement from the Cabinet Office can be found on their website.